Inclusion Criteria:

1. All patients must have histological proof of malignant cancer, which is metastatic.
Histological proof may be obtained from the primary tumor or another metastatic site.
However, cytology alone is not an acceptable method of diagnosis.

2. All patients must have greater than 3 but less than or equal to 10 metastatic lesions
seen on a contrast enhancing MRI scan obtained not less than one month prior to study
enrollment. Patients who are found to have 11-15 metastatic lesions at the time of
treatment planning (on volumetric MRI once the head frame is in place) may still
participate in the trial.

3. All patients must be >/= 18 years of age.

4. All patients must sign informed consent verifying that they are aware of the
investigational nature of this study in keeping with the rules and policies of M.D.
Anderson Cancer Center. The only acceptable consent form is the one attached at the
end of this protocol, and it must have been approved and amended by the M.D. Anderson
IRB.

5. All patients must be eligible to have all lesions treated with SRS (i.e. maximum
diameter of largest lesion < 3.5cm) as determined by the study radiation oncologist .

6. All patients must have adequate liver, renal, and hematologic function as defined by
Aspartate Amino Transferase (AST)/Alanine Amino Transferase (ALT)/Alkaline
Phosphatase < 2.5 times normal, calculated creatinine clearance > 30ml/min, and
platelet count > 50,000.

7. All patients should have normal coagulation, with international normalized ratio
(INR) < 1.3 and able to withhold anti-coagulation medications a minimum of 24 hours
prior to radiosurgery (or until INR normalizes), on the day of treatment and 24 hours
after radiosurgery has concluded. Those patients getting WBRT may continue these
medications.

8. Patients can be undergoing concurrent systemic therapy, such as temozolomide, at the
discretion of their treating oncologist.

Exclusion Criteria:

1. Patients are excluded from this trial if they have melanoma, small cell carcinoma,
lymphoma/leukemia, or germ cell histology (note, melanoma patients will be eligible
for the sister trial to this trial which will be open simultaneously).

2. Patients will be excluded if they have had prior surgical resection of metastatic
cancer from the brain.

3. Patients will be excluded if there are one or more lesions in the brainstem.

4. Patients will be excluded if there is radiographic or CSF cytological evidence of
leptomeningeal disease.

5. Patients will be excluded if they have had prior radiation to the brain (either WBRT,
prophylactic cranial irradiation (PCI), or SRS).

6. Female patients of childbearing age will be excluded if they are pregnant as assessed
by serum b-HCG or urine pregnancy test. A serum b-HCG test or urine pregnancy test
will be performed no greater than 14 days prior to study registration.

7. Patients will be excluded if they are unable to obtain an MRI scan.

8. Patients will be excluded if they have < 4 lesions, or > 10 lesions at enrollment or
> 15 lesions at the time of treatment (note: patients who qualify for enrollment
based on having 4-10 lesions, but who are discovered to have 11-15 lesions on the
volumetric MRI used for treatment planning will be allowed to continue on study).